Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients With Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure
← catalyst calendarNCT07694297 · readout ≤ 377 d
Sponsored by Genfit (industry) · GNFT.PA — their whole pipeline →.
Phase
Phase 2
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
16estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Oct 2026 | estimated | When the study began enrolling |
| Primary completion | Aug 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Acute Decompensation of Liver Cirrhosis
- Established Acute-on-Chronic Liver Failure
Intervention
- Drug: NTZ 500mg BID on top of SOC
Primary outcome
what the primary-completion date above is the date OFTo evaluate the safety of 500 mg BID NTZ administered perorally
measured over 7 days on top of SOC follow-up period up to Day 28.
Permalink · GNFT.PA's whole pipeline · Catalyst calendar · Every registered study · What changed